LFCR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lifecore Biomedical Inc (LFCR) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has positive news catalysts and revenue growth, the technical indicators are bearish, and the financial performance shows significant net income and EPS declines. Additionally, options data indicates a bearish sentiment, and there are no strong proprietary trading signals to recommend immediate action.
The technical indicators for LFCR are bearish. The MACD histogram is negative and expanding downward, the RSI is neutral at 33.809, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 7.118, with key support at 6.816 and resistance at 7.42.
The company has signed a development services agreement with Indomo to advance a corticosteroid drug candidate, DT-001, into Phase 2 clinical trials. DT-001 has significant market potential, targeting 50 million people in the U.S. affected by acne. Revenue increased by 25.92% YoY in Q1 2026, and gross margin improved by 14.81% YoY.
The MACD and moving averages indicate a bearish trend, and options data reflects bearish sentiment. No significant insider or hedge fund activity was noted, and there are no recent congress trading data or proprietary trading signals to support a buy decision.
In Q1 2026, revenue increased to $31.1M (+25.92% YoY), but net income dropped to -$10.91M (-32.76% YoY), and EPS fell to -0.29 (-45.28% YoY). Gross margin improved to 25.04% (+14.81% YoY), but overall profitability remains a concern.
No recent analyst rating or price target data is available for LFCR.
